CClinicalTrials.gg
Not yet recruitingNCT07511231ADOPT-PCIUpdated Apr 6, 2026

Angiography-Derived Physiological Indices for Outcome Prediction in Patients Undergoing OCT-Guided PCI

An observational study in Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), sponsored by Beijing Anzhen Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Beijing Anzhen Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,800
Ages
18 Years to 84 Years
Sex
All
01

Study summary

The primary design of this study is an ambispective observational cohort study. In patients undergoing successful optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) with post-procedural angiographic images suitable for computational analysis, this study aims to evaluate the prognostic value of post-PCI angiography-derived physiological indices, specifically angiography-derived fractional flow reserve (Angio-FFR) and angiography-derived index of microcirculatory resistance (Angio-IMR), beyond conventional clinical risk factors and OCT-derived anatomical parameters. Specifically, the objectives are:

  1. To determine the associations of post-PCI Angio-FFR and Angio-IMR with the risk of Major Adverse Cardiovascular Events (MACE) during follow-up.
  2. To evaluate the incremental prognostic value of post-PCI Angio-FFR and Angio-IMR when added to models incorporating baseline clinical characteristics and OCT-derived anatomical parameters for predicting MACE.
  3. To assess whether the combined evaluation of Angio-FFR and Angio-IMR improves identification of residual risk after anatomically optimized, OCT-guided PCI.
Read the detailed description

Optical coherence tomography (OCT) provides high-resolution intravascular imaging and enables detailed assessment of stent expansion, stent apposition, and edge-related complications, making it an important tool for optimizing PCI in complex coronary lesions. Contemporary guidelines support intravascular imaging-guided PCI, and OCT-guided PCI has improved the anatomical quality of stent implantation compared with angiography-guided procedures. Nevertheless, adverse cardiovascular events continue to occur in a proportion of patients despite apparently successful OCT-guided PCI, suggesting that anatomical optimization alone may not fully eliminate post-procedural risk.

The final physiological result after PCI is determined not only by the local anatomical result within the treated segment but also by residual diffuse epicardial disease and the status of the coronary microcirculation. Previous studies have shown that residual ischemia and microvascular dysfunction may persist even after angiographically successful PCI. Because OCT primarily evaluates epicardial structural features, it cannot directly assess global physiological reserve or microvascular function. These unrecognized functional abnormalities may therefore represent an important source of residual risk after otherwise anatomically optimized PCI.

Pre-procedural physiologic characterization may further improve understanding of this residual risk. Pullback pressure gradient (PPG) quantifies the longitudinal pattern of coronary pressure loss and helps distinguish focal from diffuse epicardial disease. Lower PPG values suggest a more diffuse disease pattern, in which anatomically successful PCI may still yield limited physiological improvement because pressure loss is distributed along the vessel rather than concentrated at a focal stenosis. By contrast, higher PPG values are more consistent with focal disease and a greater potential for physiological recovery after PCI. Accordingly, pre-PCI PPG may provide complementary baseline information for interpreting residual ischemia after anatomically optimized PCI.

In this context, post-PCI functional assessment may provide clinically relevant complementary information. Angiography-derived fractional flow reserve (Angio-FFR) enables physiological assessment of the epicardial coronary circulation, whereas angiography-derived index of microcirculatory resistance (Angio-IMR) provides an estimate of coronary microvascular function. Both indices can be derived from routine post-procedural angiographic images without additional pressure-wire manipulation or pharmacologically induced hyperemia. In general PCI populations, lower post-PCI physiological values and higher microvascular resistance have been associated with worse clinical outcomes, supporting a complementary rather than competitive relationship between anatomical and physiological assessment.

Nevertheless, the applicability of these findings to patients undergoing OCT-guided PCI remains uncertain. Compared with conventional angiography-guided or mixed PCI cohorts, patients selected for OCT-guided PCI often have more complex lesion characteristics and may achieve a higher level of stent optimization. Accordingly, the distribution, composition, and prognostic relevance of residual functional abnormalities may differ in this specific population. More importantly, it has not been directly established whether Angio-FFR and Angio-IMR continue to provide incremental prognostic information after OCT-defined anatomical optimization has been achieved, whether Angio-IMR offers additional value beyond Angio-FFR in this setting, or whether pre-PCI PPG provides complementary information for identifying patients at risk of suboptimal physiological recovery.

Therefore, this study is designed as a multicenter, ambispective observational cohort study led by the National Clinical Research Center for Cardiovascular Diseases and conducted across multiple collaborating centers in China, integrating retrospective and prospective cohorts of patients undergoing successful OCT-guided PCI. Post-procedural Angio-FFR and Angio-IMR will be derived from angiographic images suitable for computational analysis, and their prognostic value will be evaluated in conjunction with baseline clinical characteristics and OCT-derived anatomical parameters. Pre-PCI PPG will also be explored as an adjunctive baseline physiological marker in multivariable analyses. The primary outcome is Major Adverse Cardiovascular Events (MACE), defined as a composite of all-cause death, spontaneous target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, hospitalization for unstable angina, and hospitalization for heart failure. All enrolled patients will undergo a minimum of 24 months of follow-up. By systematically assessing the incremental prognostic value of post-PCI Angio-FFR and Angio-IMR, while exploring the complementary contribution of pre-PCI PPG, this study aims to provide an evidence base for refined risk stratification and individualized post-PCI management after OCT-guided PCI.

02

Conditions studied

  • Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))

Keywords

  • Optical Coherence Tomography
  • OCT-guided PCI
  • Angiography-derived Fractional Flow Reserve
  • Angiography-derived Index of Microcirculatory Resistance
  • Pullback Pressure Gradient
  • Major Adverse Cardiovascular Events
03

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with coronary artery disease undergoing successful OCT-guided PCI with stent implantation at participating centers in China, with post-procedural angiographic images suitable for computation of pre-PPG and post-Angio-FFR and post- Angio-IMR.

Eligibility criteria

Inclusion Criteria:-1.Age >= 18 years and \< 85 years. 2.Successful stent implantation under OCT guidance. 3.Availability of at least two optimal post-PCI angiographic projections separated by > 25 degrees and suitable for angiography-derived physiological analysis.

-

Exclusion Criteria:1.PCI of the culprit vessel for ST-segment elevation myocardial infarction (STEMI).

2.Cardiogenic shock or requirement for mechanical circulatory support. 3.Life expectancy of less than 1 year. 4.History of coronary artery bypass grafting (CABG). 5.Balloon angioplasty without stent implantation. 6.Severe procedural complications, including intraprocedural death, emergency CABG, or coronary perforation.

7.Target-vessel diameter \< 2.5 mm. 8.Heart failure with New York Heart Association (NYHA) class III-IV symptoms or left ventricular ejection fraction (LVEF) \< 30%.

-

04

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective cohort

    Patients who underwent successful OCT-guided PCI with stent implantation during the retrospective study period (January 2020 to March 2026) at participating centers in China where eligible archived angiographic, OCT, and follow-up data are available for analysis.

    Procedure: OCT-guided PCI

  • Prospective cohort

    Patients newly enrolled during the prospective study period (March 2026 to March 2027) at participating centers in China who undergo successful OCT-guided PCI with stent implantation and have post-procedural angiographic images suitable for Angio-FFR and Angio-IMR analysis.

    Procedure: OCT-guided PCI

Interventions

  • ProcedureOCT-guided PCI

    Not applicable as assigned study interventions. This is an observational study. OCT-guided PCI will be performed according to routine clinical practice at each participating center. Coronary angiographic images obtained before and after PCI will be used to derive angiography-based physiologic indices, including pre-PCI pullback pressure gradient (PPG) and post-PCI Angio-FFR and Angio-IMR, for physiologic characterization and outcome analysis.

05

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events

    MACE is defined as the first occurrence of any of the following events: all-cause death, spontaneous target-vessel myocardial infarction, ischemia-driven target-vessel revascularization, hospitalization for unstable angina, or hospitalization for heart failure.

    Time frame: Up to 24 months after the index PCI

Secondary outcomes

  1. All-cause death

    Occurrence of death from any cause.

    Time frame: Up to 24 months after the index PCI

  2. Spontaneous target-vessel myocardial infarction

    Spontaneous myocardial infarction involving the target vessel. Periprocedural myocardial infarction will not be included.

    Time frame: Up to 24 months after the index PCI

  3. Ischemia-driven target-vessel revascularization

    Repeat revascularization of the target vessel performed because of recurrent ischemia.

    Time frame: Up to 24 months after the index PCI

  4. Hospitalization for unstable angina

    Hospitalization for unstable angina meeting clinical diagnostic criteria.

    Time frame: Up to 24 months after the index PCI

  5. Hospitalization for heart failure

    Hospitalization for heart failure meeting clinical diagnostic criteria.

    Time frame: Up to 24 months after the index PCI

  6. Seattle Angina Questionnaire (SAQ) score

    Residual ischemia-related health status assessed using the Seattle Angina Questionnaire across the domains of physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life.

    Time frame: At 6, 12, and 24 months after the index PCI

06

Study locations

1 site
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
07

References and documents

Publications

  • Ikeda K, Mizukami T, Sakai K, Bouisset F, Sonck J, Wilgenhof A, Matsuo H, Shinke T, Ando H, Hada M, Ko B, Biscaglia S, Rivero F, Engstrom T, Leone AM, van Nunen LX, Fearon WF, Christiansen EH, Fournier S, Desta L, Yong A, Adjedj J, Escaned J, Nakayama M, Eftekhari A, Keulards D, Zimmermann FM, Storozhenko T, da Costa BR, Campo G, Berry C, Collison D, Johnson TW, Munhoz D, Amano T, Perera D, Jeremias A, Ali ZA, Kubo T, Satomi K, Tanaka N, De Bruyne B, Johnson NP, Collet C. Impact of Pullback Pressure Gradient on Clinical Outcomes after Percutaneous Coronary Interventions. Circ Cardiovasc Interv. 2025 Dec;18(12):e016022. doi: 10.1161/CIRCINTERVENTIONS.125.016022. Epub 2025 Oct 25. PubMed 41137850 ↗
  • Johnson TW, Bergmark BA, Croce K, Pellegrini D, Maehara A, Gori T, Pinilla-Echeverri N, Wollmuth J, Gonzalo N, Kao HL, Guagliumi G, Phalakornkule K, Ediebah D, McNutt J, Chiu WC, Op den Buijs J, Buccola J, Landmesser U, Ali Z, Stone GW, Jeremias A. Impact of Optical Coherence Tomography-Based Post-PCI Physiology Assessment to Predict Clinical Outcomes: An ILUMIEN-IV Substudy. J Am Coll Cardiol. 2025 Jul 15;86(2):93-102. doi: 10.1016/j.jacc.2025.05.019. Epub 2025 May 22. PubMed 40406943 ↗
  • Wang D, Li X, Feng W, Zhou H, Peng W, Wang X. Diagnostic and prognostic value of angiography-derived index of microvascular resistance: a systematic review and meta-analysis. Front Cardiovasc Med. 2024 Apr 15;11:1360648. doi: 10.3389/fcvm.2024.1360648. eCollection 2024. PubMed 38685980 ↗
  • Hwang D, Lee JM, Yang S, Chang M, Zhang J, Choi KH, Kim CH, Nam CW, Shin ES, Kwak JJ, Doh JH, Hoshino M, Hamaya R, Kanaji Y, Murai T, Zhang JJ, Ye F, Li X, Ge Z, Chen SL, Kakuta T, Koo BK. Role of Post-Stent Physiological Assessment in a Risk Prediction Model After Coronary Stent Implantation. JACC Cardiovasc Interv. 2020 Jul 27;13(14):1639-1650. doi: 10.1016/j.jcin.2020.04.041. PubMed 32703590 ↗
  • Biscaglia S, Tebaldi M, Brugaletta S, Cerrato E, Erriquez A, Passarini G, Ielasi A, Spitaleri G, Di Girolamo D, Mezzapelle G, Geraci S, Manfrini M, Pavasini R, Barbato E, Campo G. Prognostic Value of QFR Measured Immediately After Successful Stent Implantation: The International Multicenter Prospective HAWKEYE Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):2079-2088. doi: 10.1016/j.jcin.2019.06.003. Epub 2019 Sep 25. PubMed 31563688 ↗
  • Murai T, Yonetsu T, Kanaji Y, Usui E, Hoshino M, Hada M, Hamaya R, Kanno Y, Lee T, Kakuta T. Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome. Catheter Cardiovasc Interv. 2018 Nov 15;92(6):1063-1074. doi: 10.1002/ccd.27529. Epub 2018 Feb 15. PubMed 29446567 ↗
  • Jeremias A, Davies JE, Maehara A, Matsumura M, Schneider J, Tang K, Talwar S, Marques K, Shammas NW, Gruberg L, Seto A, Samady H, Sharp A, Ali ZA, Mintz G, Patel M, Stone GW. Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):1991-2001. doi: 10.1016/j.jcin.2019.05.054. PubMed 31648761 ↗
  • Lee SJ, Lee SJ, Hong SJ, Cho DK, Kim JW, Kim SM, Hur SH, Heo JH, Jang JY, Koh JS, Won H, Lee JW, Hong SJ, Kim DK, Choe JC, Lee JB, Yang TH, Lee JH, Hong YJ, Ahn JH, Lee SH, Lee YJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Lee JY, Kim BK. Optical coherence tomography-guided stent optimization for complex coronary lesions: the OCCUPI trial. Eur Heart J. 2026 Feb 9;47(5):608-621. doi: 10.1093/eurheartj/ehaf884. PubMed 41259082 ↗
  • Holm NR, Andreasen LD, Neghabat O, Laanmets P, Kumsars I, Bennett J, Olsen NT, Odenstedt J, Hoffmann P, Dens J, Chowdhary S, O'Kane P, Bulow Rasmussen SH, Heigert M, Havndrup O, Van Kuijk JP, Biscaglia S, Mogensen LJH, Henareh L, Burzotta F, H Eek C, Mylotte D, Llinas MS, Koltowski L, Knaapen P, Calic S, Witt N, Santos-Pardo I, Watkins S, Lonborg J, Kristensen AT, Jensen LO, Calais F, Cockburn J, McNeice A, Kajander OA, Heestermans T, Kische S, Eftekhari A, Spratt JC, Christiansen EH; OCTOBER Trial Group. OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions. N Engl J Med. 2023 Oct 19;389(16):1477-1487. doi: 10.1056/NEJMoa2307770. Epub 2023 Aug 27. PubMed 37634149 ↗
  • Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, Price MJ, Hill JM, Akasaka T, Prati F, Bezerra HG, Wijns W, Leistner D, Canova P, Alfonso F, Fabbiocchi F, Dogan O, McGreevy RJ, McNutt RW, Nie H, Buccola J, West NEJ, Stone GW; ILUMIEN IV Investigators. Optical Coherence Tomography-Guided versus Angiography-Guided PCI. N Engl J Med. 2023 Oct 19;389(16):1466-1476. doi: 10.1056/NEJMoa2305861. Epub 2023 Aug 27. PubMed 37634188 ↗
  • Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177. No abstract available. PubMed 39210710 ↗

Individual participant data

Plan to share: No — Due to patient privacy and ethical restrictions

08

Registry details

Key details

Study ID
NCT07511231
Lead sponsor
Beijing Anzhen Hospital
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Apr 6, 2026

Study contacts

Chenchen Tu, Doctor
Contact
tcc2033@mail.ccmu.edu.cn
+8615201648899
min zhang
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion